This study was designed to establish the feasibility of the mouse as a model for the investigations of (1) the cardiac myopathy associated with daunorubicin (DNR) administration and (2) the mitigation of this disorder by pretreatment with razoxane (RZ). BDF, mice were divided into three groups: '12 mice were injected at 6-weekly intervals with DNR; a second group of 12 mice received the same regimen but, in addition, were pretreated each time with RZ; a third group was injected with the carrier only. Ten/twelve mice injected with DNR died within the length of the experiment (6 weeks), while 9/12 of the pretreated animals survived that time span. Four of the DNR-exposed group were sacrificed prior to death to permit ultrastructural examination. All 9 surviving RZpretreated mice were processed for electron microscopy. Myocardial tissue was also examined light microscopically and histochemically. The ultrastructure of the DNR-treated myocardium showed a number of focally distributed abnormalities, including changes in nuclear topography, early alterations demarcated by lysosomal aggregations, and dilatations of the sarcoplasmic reticulum, and more severe lesions consisting of large, coalesced vacuolar spaces within the cardiomyocytic cytoplasm and extensive distortion of the myofibrillar architecture. The heart protected by RZ, in general, only showed either minimal or mild changes. In a few animals, the protection did not appear to be as effective as in the majority of the pretreated mice. However, extensive structural alterations were never seen in the RZ-protected myocardium. These results confirm our previous preliminary findings that a DNR-associated cardiomyopathy is inducible in mice and that pretreatment with RZ may mitigate the structural alterations in this disorder.
INTRODUCTION
nthracyclines have been used effectively in the treatment of neoplasms. In particular, dox-A orubicin and its analog daunorubicin (DNR) are commonly utilized agents in the therapeutic regimen for a variety of solid malignant tumors and acute leukemia.") Their efficacy, however, has been impaired by a number of complications associated with administration of these drugs.(') Prominent among these is the development of a dose-dependent cardiomyopathy, (2' The cardiac pathomorphology of the anthracycline-treated patient has been described, consisting primarily of mitochondria1 swelling, vacuolation of the sarcoplasmic reticulum, myocytolysis, and nuclear degeneration. ( 4 ) Attempts were also made to induce the cardiomyopathy experimentally in order to obtain information on its etiology and pathogenesis. A variety of species served as useful models for the induction of the anthracycline-associated cardiotoxicity.(s-7) These investigations revealed essentially similar structural alterations in the various species examined, including man. ( s J A bisdiketopiperazine derivative, ICRF-159 (razoxane), has been utilized as an agent for the reduction of tumor growth. This drug was synthesized originally by the laboratories of the Imperial Cancer Research Fund in Britainf8) and was subjected to clinical trials by Hellmann et al. ( 9 ) Additionally, the effectiveness of razoxane (RZ) was explored in studies designed to ameliorate the anthracycline-associated cardiotoxicity by administering razoxane prior to DNR therapy.'") The results of this intervention showed that survival time of animals exposed to DNR was prolonged with RZ pretreatment and that toxic biochemical effects were modified in these animals. This modifying activity of the DNR toxicity was investigated by one of us (G.M.W.), with results that indicated that a major site of protection in mice was situated in the small bowel.(") In addition, we have reported the outcome of an initial study concerned with the induction of a cardiomyopathy following DNR treatment and its modification by a protective pretreatment with R2.(I2)
The present contribution represents an extension of this preliminary study and was designed to confirm the feasibility of the mouse as an appropriate model for the investigation of a DNR-induced cardiotoxicity and the protective effects exerted on the myocardial ultrastructure by RZ pretreatment.
MATERIALS AND METHODS
Male BDF, mice (Jackson Laboratory, Bar Harbor, Maine), weighing approximately 20 g each, were placed ad libitum on laboratory chow and water. After 1 week of acclimatization, the mice were separated into the following groups:
Group I: 12 mice, injected ip, at 6 weekly intervals, with DNR (Sigma), 2 rng/kg body weight in 0.5 ml saline, for a total cumulative dose of 12 mg DNR Group 11: 12 mice, subjected to the same regimen as above, but, in addition, pretreated with RZ, 200 mg/kg body weight in 0.5 ml carboxymethylcellulose, 24 hours prior to each DNR administration Group III: 6 mice, injected with carboxymethylcellulose only, served as normal controls Mice were sacrificed with an excess dose of sodium pentobarbital, either at a time of entering a moribund state, or 1 day, 1 week, or 3 weeks following the sixth injection, at the termination of the experiment.
The animals were perfused at physiological pressures (120 mm Hg) via the left cardiac ventricle with 3% glutaraldehyde in Sorensen's phosphate buffer, at pH 7.2. Representative 1 mm cubes of ventricular myocardial tissue from each animal were postfixed with 1% osmium tetroxide in Millonig's buffer at the same pH. Following dehydration and embedding in epon-araldite, ultrathin sections were viewed in a JEOL 100 CX electron microscope. For orientation by light microscopy, 1 fim thick sections were stained with alkaline methylene blue. Cardiac tissue not utilized for electron microscopy, and major organs, other than the heart, were processed for embedding in paraffin and subsequent examination by light micrscopy, utilizing H & E and trichrome stains and the periodic acid-Schiff reaction.
In a second experiment designed to assess histochemical alterations in the acutely DNR-toxic heart, 6 mice were injected IP with one dose of DNR, 20 mg/kg body weight in 0.5 ml saline. These animals and 2 saline-injected normal controls were sacrificed by decapitation on the third and fourth day following the injection. Transverse slices of heart were quenched in liquid nitrogen at -150°C and 12 pm thick sections were cut in a cryostat. Reactions were performed on adjacent sections for the presence of acid phosphata~e"~) and succinic dehydrogenase.(*4) The remainder of the heart was processed for electron microscopy and routine light microscopy.
RESULTS
Mice injected with DNR failed to gain weight, unlike mice injected with the carrier only. At the time of sacrifice, the average body weight of mice in both DNR-injected groups, with and without RZ pretreatment, was reduced substantially compared with that of the untreated controls. During the third week following the initial weekly injection with DNR, mice in group I began to die. Death of mice in group I1 (pretreated with RZ) started to occur as late as the fifth week following the initial treatment. For purposes of tissue recovery, animals were categorized as indicated in Table 1 . Tissues from cannibalized mice were not available for microscopic examination. In mice which were found dead without cannibalization, tissue processing was limited to light microscopic evaluation only. Animals were considered moribund when entering a condition characterized by listlessness, partial eye closure, and a hunched (arched back) posture. Tissues from these and Ronsymptomatic mice were utilized for electron microscopy.
LIGHT MICROSCOPY
Lesions within cardiac muscle cells were clearly identifiable in epoxy-embedded 1 pm thick sections of DNR-injected mice and, characteristically, were composed of distinct vacuolations within the myocytic cytoplasm, loss of banding patterns, and a granular degeneration of individual muscle fibers ( Figs. 1 and 2) . These abnormalities were observed in mice on multiple low doses of DNR, as well as in those receiving one high dose. In paraffin-embedded, 6 pm thick sections, an isolated hypereosinophilic muscle fiber, at times with granular-appearing cytoplasm, was observable. The alterations, however, were not sufficiently clear-cut to permit an unequivocal determination of their significance. No abnormalities were evident in group I1 (RZ-pretreated) mice.
ULTRASTRUCTURE

Group I (DNR-injected)
Electron microscopic examination of myocardial ventricular tissue revealed a variety of focally distributed abnormalities. These ranged from a few nuclei with markedly invaginated nuclear membranes (Fig. 3) , early myocytic alterations demarcated by lysosomal aggregations (Fig. 4) , and dilatations of the sarcoplasmic reticulum (Fig. 5 ) to more extensive degenerative lesions consisting of large, coalesced vacuolar spaces, membrane-bound within the myocytic cytoplasm (Fig. 6) , substantial accumulations of interfibrillar edema (Fig. 7 ) , and severe distortion of the myofibrillar architecture, with loss of myocytic striations (Fig. 8) . The myocardial ultrastructure in mice used in a second experiment, primarily for histochemical evaluation, showed changes as described above but with an earlier onset, within 3 days following the administration of one high dose of DNR (20 mg/kg).
Group II (DNR-injected, RZ-pretreated)
The myocardium in DNR-injected mice, pretreated with RZ, in general showed only early changes of a DNR cardiomyopathy. Essentially, these consisted of a translucency of the sarcoplasm, associated with moderate dilatation of the sarcoplasmic reticulum and lysosomal aggregations (Figs. 9  and 10) . In a few animals, the protective pretreatment with RZ did not appear to be as effective as in the majority of pretreated mice. The myocardium in these animals showed lesions that resembled, to a moderate degree, those seen in unprotected mice (Fig. 11) . However, severe, extensive lesions were not observed in the RZ-protected myocardium.
HISTOCHEMISTRY
Frozen sections of DNR-exposed myocardium examined for the presence of acid phosphatase reaction products showed a few positively reacting myocardial fibers (Fig. 12 ) and an appearance of mononuclear cells, particularly within perivascular spaces (Fig. 13) . Cells containing coarse acid phosphatase-positive granules, suggestive of mast cells, also were seen conspicuously. No difference in reactivity for succinic dehydrogenase was noted between DNR-injected and control mice.
FIG. 9.
Mouse injected with 12 mg DNR, as previously indicated, and pretreated with a total dose of 1200 mg razoxane. Cardiomyocyte shows only moderate dilatation of sarcoplasmic reticulum (arrows). Electron micrograph. x SOOO. 182
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FIG. 10.
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Focus of moderate sarcoplasmic translucency in mouse pretreated as in Figure 9 . Electron Myocardium of DNR-treated mouse, processed as in Figure 12 . Positively reacting
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DISCUSSION
This study was designed to confirm the practicability of inducing in the mouse the cardiomyopathy that is known to develop subsequent to DNR therapy and to demonstrate the mitigating effects, if any, of RZ pretreatment on the cardiotoxic manifestations associated with DNR exposure.
Findings of note in this investigation include (1) the presence of a cardiomyopathy in DNRinjected mice that, in its ultrastructural alterations, exhibits the pathomorphologic hallmarks of the anthracycline-injured myocardium, (2) the amelioration of these myocardial abnormalities by instituting a regimen of pretreatment with RZ, and (3) the persistence of DNR-induced lesions in a small number of our RZ-protected animals, suggesting the approach of a maximum DNR dosage level, beyond which exertion of a protective action by RZ may be difficult to attain.
The induction of an anthracycline-associated cardiomyopathy in mice was reported first by Rosenoff et a1., (6) who administered a DNR analog, adriamycin. A number of microscopic abnormalities in the myocardium of these mice were noted, including vacuolization of the sarcotubular system, mitochondria1 degeneration, and myocytolysis. These lesions resembled the alterations seen in a number of other commonly used laboratory animals, including the rabbit,fs) rat,(') and Golden hamster. (I5) Application of the endomyocardial biopsy procedure permitted a quantitative grading of the lesions in the anthracycline-exposed human heart . ( 4 ) These studies demonstrated convincingly that the mammalian heart responds to the anthracycline insult by presenting a number of common changes, ranging from reversible abnormalities, such as sarcotubular vacuolations, to more severe myofibrillar degeneration with, finally, irreversible cardiomyocytolysis. The lesions that we have observed in our DNR-treated mice reflect this pattern, with the exception that significant mitochondria] swelling and degeneration were not observed, and, hence, we feel certain that these characteristic structural alterations can be induced effectively in the mouse injected with DNR. This finding is in contrast with the observations of Strohm et who attempted to utilize the mouse as a model for a study of the ultrastructural pathomorphology associated with a chronic doxorubicin cardiotoxicity. It is difficult to discover a basis for this discrepancy. However, the failure to demonstrate the presence of vacuolations of the sarcotubular system or myocytic necroses may be due to the fact that these lesions are highly focal in distribution and may not be as prevalent within the interventricular septum (examined in their study) as in the left ventricle, a common, primary site of myocardial abnormalities and, specifically, the locus of severe lesions in the anthracycline-injured heart. 17 ) The conspicuous change in the morphology of the sarcoplasmic reticulum in the DNR-treated heart may be the expression of an abnormal myocardial function, in view of the reported increase of calcium concentration in animals receiving an anthracycline. (I8) It was also suggested that such calcium accumulation and binding within the sarcoplasmic reticulum represented the initial event of cardiac failure. One can reasonably expect that the pathomorphological consequences of such a scheme would be manifested particularly in the early, acute phase of the myopathy. However, it has been shown that this lesion is observed more prominently in association with the later stages of a chronic cardiotoxicity. (''I A clarification of this issue was beyond the scope of the study reported in this contribution. Hence, we intend to pursue this aspect by carrying out a detailed, sequential investigation of the ultrastructure in the DNR-treated myocardium, which may provide additional information on these relationships.
The ultrastructural examination of myocardial tissue in our study offers evidence, strengthened by the demonstration of focal acid phosphatase reactivity in the DNR-exposed mice, for an involvement of the lysosomal system in the myocardial response to the pharmaceutical insult. The noticeable presence of dark bodies at an early stage of the myocardial alterations is likely to provide the basis for the later, irreversible lesions, culminating in myofibrillar necrosis.
The amelioration of the cardiotoxic effects associated with anthracycline therapy by pretreatment with RZ was studied extensively by Herman et a1.(10~20) Recent additional reports by Herman et aI.,(" using the D-isomer of RZ, ICRF-187, confirmed the previously established mitigating effects of RZ. By light microscopy, the incidence of vacuolations within myocardial cells of pretreated hamsters was substantially reduced, while the hearts of rabbits protected by RZ either failed to show abnormalities or exhibited only mild structural changes.
The results of our investigations support these findings and indicate that a protective action by RZ on the myocardium is noticeable also at the ultrastructural level. Although our study did not permit a definitive statistical assessment of the mitigating effect associated with RZ pretreatment, the myocardium protected by RZ only showed either minimal or mild, clearly reversible changes. Severe, irreversible lesions, characterized by myofibrillar necrosis, were not seen in the RZ-protected heart.
Of interest is the finding that a small number of our RZ-pretreated mice failed to show a protection as effective as that manifested by the majority of our pretreated mice. At this time, the basis for the inadequacy of the mitigating effect by RZ cannot be identified clearly; the individual susceptibility of mice to treatment may be a factor to consider. However, it is also likely that the total cumulative dose of DNR that we injected into our mice may constitute a saturation dosage level, contributing to the inability of RZ to exert its maximum protective action in some of the mice. It remains to be seen whether a modification of RZ pretreatment dosages can overcome this insufficiency.
In conclusion, this follow-up investigation to our initial exploration of a DNR-induced cardiomyopathy in the mouse and its mitigation by RZ has confirmed our previous findings that such a cardiomyopathy with clearly identifiable features is inducible and that the lesions within the DNRexposed myocardium are modifiable in their severity by a protective pretreatment with RZ. The need is evident for additional studies, in order to identify the precise locus of drug-myocytic interaction and to define the mechanism of the protective action exerted by RZ.
